Dyne Therapeutics wins FDA Priority Review for DMD drug z-rostudirsen, with key catalysts and pipeline upside. Click for more ...
Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion ...
Investor's Business Daily on MSN
Sarepta skids after a rival clears a key hurdle in the Duchenne space
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
19d
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?
US biotech Dyne Therapeutics has moved closer to a possible first approval after the US Food and Drug Administration accepted ...
Dyne Therapeutics Inc (NASDAQ:DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with ...
- Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 - WALTHAM, Mass., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Dyne ...
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ...
It isn't unusual for a biotech to raise capital after it posts positive results from a clinical trial. In the case of a new fundraising effort by Dyne Therapeutics (NASDAQ: DYN), however, investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results